.2pCD (FCG2), and pAG2 (AT3). The restriction fragment length polymorphisms (RFLPs) are described in detail in Genome Data Base (GDB). All manipulations, including isolation of genomic and plasmid DNA, digestion with restriction enzymes, Southern blot transfer of genomic DNA, and hybridisation with radiolabelled plasmid DNA were done according to standard procedures.
Primers flanking the CA repeat polymorphisms RM11-GT (D17S122), Mfd3 (APOA2), and Mfd57 (CRP), respectively, and conditions of the polymerase chain reaction were as described in GDB.
The 9 In all CMT1 families analysed, the clinical picture of the patients was consistent with a CMT1 phenotype according to the diagnostic criteria agreed upon by the European CMT consortium group,20 that is, patients had slowly progressive symmetrical muscle atrophy and weakness, severely decreased motor nerve conduction velocity (median NCV <30 m/s), and absence or marked decrease of sensory nerve action potentials in the lower limbs. In only one of the three non-duplicated CMT1 families (family CMT-B) was the pedigree size sufficient for linkage analysis studies. The pedigree of family CMT-B consisted offive generations comprising 75 persons of whom 18 were clinically affected. The pattern of inheritance of the disease was autosomal dominant. Most patients had NCVs measured in the motor median nerve giving a mean value of 13 1 m/s (SD 3 3). The proband had a sensory nerve biopsy consistent with a diagnosis of demyelinating neuropathy. Blood samples for DNA analysis were obtained from 29 family members of family CMT-B (fig 1) . All patients and at risk persons in generations III to V had a neurological examination. Most patients had an electrophysiological examination to confirm their disease status while only one asymptomatic at risk person (IV. 17) had NCVs measured that were normal.
LINKAGE ANALYSIS
Linkage analysis was performed in family CMT-B using RFLP and CA repeat markers located on chromosomes 17pll.2-pl2 and 1q22-q25. Two family CMT-B. Unfortunately no frozen nerve biopsy material of the proband was available. Also, at that moment only the human cDNA sequence of PO was known.2' Therefore, we had to use genomic DNA for direct PCR sequencing using primers designed on the basis of the cDNA sequence of the human P0 gene.
In rat and mouse the genomic organisation of the PO gene was known, showing the intron/ exon boundaries of six exons coding for PO.
Using this information we deduced the location of the exonic sequences in the human cDNA sequence of PO assuming that human PO is also coded for by six exons. Two primer sets were designed based on the sequence of exons 2 and 3 and exons 3 and 6 respectively to amplify the genomic DNA of two affected and two unaffected subjects from family CMT-B. Subsequently the sequence of exons 2 to 6 was determined using either the primers used in the PCR amplification or internal primers designed based on the sequence of exons 4 and 5. Also, intronic sequence information obtained during the sequencing analysis was used to design additional primers. We were able to determine the complete coding sequence of exons 3, 4, 5, and 6 as well as the sequence of introns 3, 4, and 5 (the nucleotide sequence data will appear in the EMBL, GenBank, and DDBJ Nucleotide Sequence Databases under the accession numbers U10017 and U10018 The major structural peripheral myelin protein zero, P0, is localised in the lq2 1-q23 region and is a candidate gene for CMT1B. We established the sequence of the P0 gene by direct PCR sequencing in genomic DNA of patients and unaffected subjects of family CMT-B. In exon 3, a C to A mutation was detected at position 446 leading to an amino acid substitution of Asp by Glu at codon 134. The Aspl34 codon is conserved among many species, such as mouse, rat, and bovine. SSCP analysis showed that all affected subjects of the family were mutated, while the married in and mutation at clinically unaffected at risk persons were not mutation was mutated. Also, the mutation was not present lucleotide in 30 unrelated controls. These findings suggest Aspl34Glu that CMT1B disease in this family is caused Linkage and mutation analysis in an extended family with Charcot-Marie-Tooth disease type IB region, have been described. On chromosome 1, seven different mutations in the P0 gene have been found in CMT1 patients so far. Thus, CMT1 patients who are not duplicated for the CMT1A region should be screened for mutations in the P0 as well as in the PMP-22 gene to establish DNA diagnosis. CMT1 patients without CMT1A duplication or mutations in P0 or PMP-22 should be tested for mutations in other candidate genes for peripheral neuropathies. Recently, the gene coding for the gap junction protein connexin 32 (Cx32) located on chromosome Xql3.1 has been identified as the site of mutations in dominant X linked CMT1 families (CMTX).5 Therefore, in CMT1 patients in whom X linkage cannot be excluded, mutations in the Cx32 gene can also be sought.
